DuPont de Nemours, Inc. (DD) Stock Analysis
Is DD a good investment?
DuPont de Nemours, Inc. (DD) has a Plutrex AI rating of 69.0/100 as of August 20, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Fortress balance sheet: D/E of 0.23 vs industry average of 1.32 (82.6% less leverage), $1.74B cash, and $1.835B FCF — FCF dramatically exceeds GAAP net income, confirming true cash earnings power far above the 331x P/E implies; this financial resilience is unmatched in the sector. Main concern: Forward EPS growth of 9.46% vs industry average of 82.90% (88.6% deficit) — peers have dramatically larger near-term earnings recovery runways; combined with revenue growth of only 4.0% vs industry 20.13%, capital rotation risk toward higher-growth peers in a risk-on environment remains the most critical relative weakness; UNCHANGED from prior report.
Investment Summary
DuPont (DD) at $139.68 is a quality specialty chemicals compounder executing a credible turnaround, supported by exceptional balance sheet strength (D/E 0.23 vs industry 1.32), robust free cash flow of $1.835B, and a news sentiment score of 89.3/100 driven by Q2 2026 EPS beat ($1.88 adjusted vs guidance), raised full-year guidance, and strategic wins including the MemCor MBR system selection for Australia's largest inland wastewater facility. The analyst consensus target of $168.93 implies 21.0% upside. However, the stock has declined 3.3% from our prior entry midpoint of $143.75 to $139.68 — a modest deterioration that slightly improves the risk/reward but also signals near-term technical weakness. The core investment tension remains unchanged: a PEG of 0.89 (technically undervalued) against a 331x trailing P/E (artificially inflated by 0.7% net margin), with forward EPS growth of 9.46% dramatically lagging the industry average of 82.90%. The turnaround is real — net margin improved from -0.3% to +0.7%, FCF turned from -$124.75M to +$1.835B — but the pace of margin recovery from 0.7% toward the 5-8% needed to justify the valuation remains the central execution risk. At $139.68, the stock is modestly more attractive than 7 days ago, and the positive news flow (Q2 beat, guidance raise, lithium extraction portfolio launch) provides near-term catalysts. Maintain Buy with Medium conviction.
Key Strengths
- Fortress balance sheet: D/E of 0.23 vs industry average of 1.32 (82.6% less leverage), $1.74B cash, and $1.835B FCF — FCF dramatically exceeds GAAP net income, confirming true cash earnings power far above the 331x P/E implies; this financial resilience is unmatched in the sector
- Turnaround progressing with measurable evidence: net margin improved from -0.3% to +0.7%, FCF turned from -$124.75M to +$1.835B, Q2 2026 adjusted EPS of $1.88 beat guidance, full-year 2026 guidance raised — the core business is healing with positive momentum
- Strategic technology leadership in high-growth markets: MemCor MBR system selected for Australia's largest inland wastewater facility (landmark reference project for future regional sales), new end-to-end direct lithium extraction portfolio launched (named 2026 Sustainability Squad by Business), and gross margin of 32.74% (97% premium to industry) reflects durable differentiation
Key Concerns
- Forward EPS growth of 9.46% vs industry average of 82.90% (88.6% deficit) — peers have dramatically larger near-term earnings recovery runways; combined with revenue growth of only 4.0% vs industry 20.13%, capital rotation risk toward higher-growth peers in a risk-on environment remains the most critical relative weakness; UNCHANGED from prior report
- Net margin of 0.67% requires expansion to 5-8% to justify the 331x P/E and validate the 19.77% five-year EPS growth projection — the entire investment thesis depends on non-cash charges normalizing; if restructuring, amortization, or macro headwinds persist, the growth projection fails and the stock re-rates lower; UNCHANGED from prior report, though Q2 beat and guidance raise provide incremental confidence
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
DD's fundamentals present a classic 'quality compounder in turnaround' profile. Gross margin of 32.74% is nearly double the industry average of 16.61%, demonstrating durable specialty chemicals pricing power. Operating margin of 14.24% is solid and slightly above the industry average of 13.30%. The critical weakness is the 13.5 percentage point collapse from operating margin (14.24%) to net margin (0.67%), driven by non-cash charges, amortization, and restructuring — this is the defining profitability concern. ROE of 2.78% is weak in absolute terms but positive vs the industry average of -6.66% (peers are destroying equity value). The P/E of 331.35x is extreme but misleading — FCF of $1.835B dramatically exceeds implied GAAP net income (~$100-200M), meaning true cash earnings power is far higher. PEG of 0.89 signals growth-adjusted undervaluation. Price-to-Book of 1.37x is conservative. D/E of 0.23 vs industry average of 1.32 is the balance sheet standout — 82.6% less leverage than peers. Revenue growth of 4.0% vs industry 20.13% is the top-line weakness. Forward EPS growth of 9.46% vs industry 82.90% is the most damaging relative metric. The 5-year EPS growth projection of 19.77% requires margin expansion from 0.67% to 5-8% — achievable given FCF strength but dependent on non-cash charges normalizing.
News Sentiment
DuPont is quietly having a strong year — and investors are starting to notice. The specialty chemicals giant just delivered a standout second quarter for 2026, posting adjusted earnings per share of $1.88 that beat its own guidance, with operating EBITDA of $448 million. The company was so confident in its momentum that it raised its full-year 2026 guidance — a signal that management sees the good times continuing. On the technology front, DuPont is making waves in two of the hottest sectors around. The company's MemCor membrane bioreactor system was chosen to upgrade Australia's largest inland wastewater treatment facility — a landmark win that positions DuPont as the go-to technology partner for water treatment projects across the Asia-Pacific region. Think of it as a showcase project that could open doors to dozens of future contracts. Meanwhile, DuPont launched a complete end-to-end direct lithium extraction portfolio, earning recognition as a '2026 Sustainability Squad' honoree — putting the company squarely in the middle of the global battery materials supply chain that electric vehicles depend on. There's also legal clarity emerging: New Jersey's $2.5 billion 'forever chemicals' settlement with DuPont, 3M, and others removes a significant cloud of uncertainty that had weighed on the stock. The bottom line? DuPont is beating expectations, winning new contracts, entering growth markets, and resolving legal headaches — all at the same time.
Risk Assessment
PRIMARY RISK: Net margin recovery stalls at 0.67% — if restructuring charges, PFAS-related costs, or macro headwinds persist, the 19.77% five-year EPS growth projection fails and the 331x P/E becomes the dominant reality, potentially triggering a 20-30% re-rating lower. SECONDARY RISK: Capital rotation away from DD toward higher-growth peers (industry forward EPS 82.90% vs DD's 9.46%) in a risk-on environment — DD is a quality compounder, not a momentum stock, and could underperform the sector even if the turnaround succeeds. TERTIARY RISK: PFAS/forever chemicals legal exposure — the New Jersey $2.5B settlement headline (distributed across Chemours/Corteva spinoffs) removes some overhang but ongoing litigation risk remains. MITIGATION: Conservative 3.0% position size limits downside exposure. Stop loss at $130.00 (6.5% below entry midpoint of $139.00) limits maximum loss to ~$9.00/share. The $1.835B FCF and D/E of 0.23 provide fundamental floor support — the company is not at risk of financial distress. The 21.0% upside to analyst target ($168.93) and 32.3% to target_2 ($183.90) provide asymmetric reward if margin recovery accelerates.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is DD a halal stock?
No, DuPont de Nemours, Inc. (DD) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for DD?
DuPont de Nemours, Inc. (DD) has a Plutrex AI rating of 69.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is DD a good investment?
According to Plutrex AI, DD has a Buy rating (69.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in DD?
US stocks like DD can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in DD?
Plutrex AI identifies the main risks for DD by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.